Clinical Trials Logo

Irritable Bowel Syndrome clinical trials

View clinical trials related to Irritable Bowel Syndrome.

Filter by:

NCT ID: NCT04946604 Completed - Clinical trials for IBS - Irritable Bowel Syndrome

Ashtangayoga for IBS Show Positive Preliminary Effects on Symptoms and Well-being

Start date: January 18, 2018
Phase: N/A
Study type: Interventional

The study aims to test the effect of Ashtanga yoga on well-being in patients with irritable bowel syndrome (IBS). The intervention comprises group sessions on the Ashtanga school of yoga. Participants are recruited from primary care and measurements on well-being and IBS symptoms are conducted at pre-treatment, post-treatment and 6-month follow-up.

NCT ID: NCT04921709 Recruiting - Clinical trials for Irritable Bowel Syndrome

Renal Involvement in Inflammatory Bowel Disease Patients

Start date: June 1, 2021
Phase:
Study type: Observational

To evaluate renal involvement in inflammatory bowel disease patients .

NCT ID: NCT04918329 Recruiting - Clinical trials for Irritable Bowel Syndrome

Functional Digestive Disorders Observatory

OTFI
Start date: October 9, 2020
Phase:
Study type: Observational [Patient Registry]

Functional digestive pathologies are defined by symptoms such as functional dyspepsia, gastroesophageal reflux, irritable bowel syndrome, gastroesophageal reflux, functional constipation, functional diarrhea, functional bloating, the opioid-induced constipation and fecal incontinence, without organic substratum. These diseases are very common in the general population (20%) and represent the first cause of consultation in city gastroenterology. The objective of this study is to collect prospective clinical and tests data and a biological collection from biological samples collected as part of the standard care. This collection could identify diagnostic or prognostic markers of the therapeutic response.

NCT ID: NCT04905524 Completed - Depression, Anxiety Clinical Trials

Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

Viome costumers are consented and recruited for this study and complete the questionnaires upon enrollment. Any participant who previously self reported depression, anxiety, or Irritable Bowel Syndrome (IBS) qualify for this study. All participants receive Viome's diet, supplement and recommendations.

NCT ID: NCT04899869 Completed - Clinical trials for Irritable Bowel Syndrome With Diarrhea

Faecal Microbiota Transplantation in Irritable Bowel Syndrome

MISCEAT
Start date: June 17, 2021
Phase: N/A
Study type: Interventional

Irritable bowel syndrome (IBS) is the most common functional bowel disorder, being present in approximately 10% of adult Europoid population. The etiology of IBS is elusive. Literature indicates that modification of patients´colonic microbiota might ameliorate the condition. Here we test an intervention by faecal microbiota transplantation of artificially inflated microbiome diversity, versus autoclaved placebo.

NCT ID: NCT04898257 Completed - Clinical trials for IBS - Irritable Bowel Syndrome

Effect of Lactibiane Tolerance® to Treat Leaky Gut in Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)Patients

Start date: May 17, 2018
Phase: N/A
Study type: Interventional

This is a Phase IV, open-label, single-center, proof-of-concept, pilot study to evaluate the effect of Lactibiane Tolerance® in treating leaky gut in IBS-D patients. 30 consecutive patients with IBS-D and an increased intestinal permeability assessed by 51Cr-EDTA or 99mTc-DTPA will receive the multistrain probiotic Lactibiane Tolerance® 10 billion CFU 1 capsule twice a day (30 minutes before breakfast and 30 minutes before dinner) for 30 days treatment. At the end of treatment, patients will repeat intestinal permeability assessment by 51Cr-EDTA or 99mTc-DTPA.

NCT ID: NCT04893499 Completed - Clinical trials for Irritable Bowel Syndrome

A Study of Chios Mastic Water in Irritable Bowel Syndrome

MASTIQUA
Start date: September 12, 2021
Phase: N/A
Study type: Interventional

Chios mastic is a natural product with strong antimicrobial, anti-inflammatory and antioxidant properties, and well-established benefits for dyspeptic disorders. The aim of the present study is to investigate the effectiveness of a natural aqueous extract of Chios mastic (mastic water), a by-product of Chios mastic processing, in the management of irritable bowel syndrome. This will be a 3-month randomized double-blind controlled clinical trial in adult patients with irritable bowel syndrome under standard medication. Participants will be blindly randomized to a low-dose mastic group, which will receive a carbonated water enriched with Chios mastic water (0.06%), a high-dose mastic group, which will receive a carbonated fruit juice enriched with Chios mastic water (0.55%), or one of the two control groups, which will receive an identical placebo water/fruit juice with no active ingredients. Participants will be evaluated in terms of anthropometric indices, lifestyle habits, severity of IBS-related gastrointestinal symptoms, quality of life, as well as biochemical, inflammatory and oxidative stress markers, both pre- and post-intervention.

NCT ID: NCT04890405 Not yet recruiting - Clinical trials for Irritable Bowel Syndrome Variant of Childhood

Clinical Study of Selective Fecal Microbiota Transplantation in the Treatment of Irritable Bowel Syndrome.

Start date: May 20, 2021
Phase: N/A
Study type: Interventional

In order to seek a more precise and convenient treatment, we made a self-made precise transplant capsule that is effective against diarrhea. Compared with standardized fecal microbiota transplantation transplantation on the treat of diarrhea-type irritable bowel syndrome. To observe the similarities and differences of the effect between the two treatment methods on the disease. and the changes in intestinal bacteria was also observed.

NCT ID: NCT04880876 Enrolling by invitation - Clinical trials for Irritable Bowel Syndrome

A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Start date: August 13, 2021
Phase: Phase 3
Study type: Interventional

This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.

NCT ID: NCT04879914 Completed - Clinical trials for Inflammatory Bowel Diseases

Analysis of Microbiota Changes Induced by Microencapsulated Sodium Butyrate in Patients With Inflammatory Bowel Disease

IBDMicro
Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Inflammatory bowel disease (IBD) is characterized by severe inflammation of the small bowel and/or the colon leading to recurrent diarrhea and abdominal pain. Irritable Bowel Syndrome with diarrhea (IBS-D) is characterized by abdominal pain or discomfort, gas, loose and frequent stools. Butyrate has shown anti-inflammatory and regenerative properties, providing symptomatic relief when orally supplemented in patients suffering from various colonic diseases. The investigator proposes to investigate the effect of a microencapsulated form of sodium butyrate on the fecal microbiota of patients with IBD and IBS-D.